{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:00:09Z","timestamp":1791453609147,"version":"4.3.3"},"reference-count":119,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008383","name":"Stichting ParkinsonFonds","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008383","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s13311-022-01288-7","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T13:36:15Z","timestamp":1662730575000},"page":"1489-1502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective"],"prefix":"10.1016","volume":"19","author":[{"given":"Luisa","family":"Knecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Folke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2044-6299","authenticated-orcid":false,"given":"Richard","family":"Dodel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alexander","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Albus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-022-01288-7_bib1","unstructured":"Tretiakoff C. Contribution \u00e0 l'\u00e9tude de l'anatomie pathologique du locus niger de Soemmering avec quelques d\u00e9ductions relatives \u00e0 la pathogenit\u00e9 des troubles du tonus musculaire et de la maladie de Parkinson. Paris; 1919."},{"key":"10.1007\/s13311-022-01288-7_bib2","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-022-01288-7_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01288-7_bib4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","article-title":"Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders","volume":"119","author":"Beach","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-022-01288-7_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neulet.2005.11.012","article-title":"Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology","volume":"396","author":"Braak","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-022-01288-7_bib6","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/NEN.0b013e318186de48","article-title":"Lewy body pathology involves cutaneous nerves","volume":"67","author":"Ikemura","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-022-01288-7_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92295","article-title":"\u03b1-Synuclein in gut endocrine cells and its implications for Parkinson's disease","author":"Chandra","year":"2017","journal-title":"JCI Insight"},{"key":"10.1007\/s13311-022-01288-7_bib8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.24648","article-title":"Pathological \u03b1-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients","volume":"79","author":"Stokholm","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01288-7_bib9","doi-asserted-by":"crossref","first-page":"134316","DOI":"10.1016\/j.neulet.2019.134316","article-title":"\u03b1-Synuclein pathology in Parkinson's disease and related \u03b1-synucleinopathies","volume":"709","author":"Henderson","year":"2019","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-022-01288-7_bib10","doi-asserted-by":"crossref","first-page":"105332","DOI":"10.1016\/j.nbd.2021.105332","article-title":"Dermal and cardiac autonomic fiber involvement in Parkinson's disease and multiple system atrophy","volume":"153","author":"Brumberg","year":"2021","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-022-01288-7_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10030493","article-title":"Gastrointestinal dysfunction in Parkinson's disease","author":"Skj\u00e6rb\u00e6k","year":"2021","journal-title":"J Clin Med"},{"key":"10.1007\/s13311-022-01288-7_bib12","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1212\/WNL.56.7.980","article-title":"Accumulation of alpha-synuclein in autonomic nerves in pure autonomic failure","volume":"56","author":"Kaufmann","year":"2001","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01288-7_bib13","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1212\/WNL.46.5.1470","article-title":"Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy","volume":"46","author":"The Consensus Committee of the American Autonomic Society and the American Academy of Neurology","year":"1996","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01288-7_bib14","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.mayocp.2019.03.009","article-title":"Pure autonomic failure","volume":"94","author":"Coon","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1007\/s13311-022-01288-7_bib15","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1007\/s13311-022-01288-7_bib16","doi-asserted-by":"crossref","first-page":"e889","DOI":"10.1212\/WNL.0000000000010002","article-title":"Predicting phenoconversion in pure autonomic failure","volume":"95","author":"Coon","year":"2020","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01288-7_bib17","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1212\/WNL.0000000000003737","article-title":"Pure autonomic failure: Predictors of conversion to clinical CNS involvement","volume":"88","author":"Singer","year":"2017","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01288-7_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-5793(94)00395-5","article-title":"Identification of two distinct synucleins from human brain","volume":"345","author":"Jakes","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1007\/s13311-022-01288-7_bib19","doi-asserted-by":"crossref","first-page":"13709","DOI":"10.1021\/bi961799n","article-title":"NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded","volume":"35","author":"Weinreb","year":"1996","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-022-01288-7_bib20","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1073\/pnas.97.9.4897","article-title":"Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation","volume":"97","author":"Serpell","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-022-01288-7_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01288-7_bib22","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of \u03b1-synuclein immunization in a mouse model of Parkinson's disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"key":"10.1007\/s13311-022-01288-7_bib23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S1474-4422(05)70129-0","article-title":"Parkinson's vaccine on trial","volume":"4","author":"Pilcher","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-022-01288-7_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000134061","article-title":"High-resolution mapping of SNCA encoding alpha-synuclein, the non-A beta component of Alzheimer's disease amyloid precursor, to human chromosome 4q21.3\u2013q22 by fluorescence in situ hybridization","volume":"71","author":"Shibasaki","year":"1995","journal-title":"Cytogenet Cell Genet"},{"key":"10.1007\/s13311-022-01288-7_bib25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s004390050792","article-title":"Identification, localization and characterization of the human gamma-synuclein gene","volume":"103","author":"Lavedan","year":"1998","journal-title":"Hum Genet"},{"key":"10.1007\/s13311-022-01288-7_bib26","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","article-title":"Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease","volume":"90","author":"U\u00e9da","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-022-01288-7_bib27","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.1021\/bi034028+","article-title":"A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein","volume":"42","author":"Du","year":"2003","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-022-01288-7_bib28","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1074\/jbc.M008919200","article-title":"A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly","volume":"276","author":"Giasson","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-022-01288-7_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/1074-5521(95)90071-3","article-title":"The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease?","volume":"2","author":"Han","year":"1995","journal-title":"Chem Biol"},{"key":"10.1007\/s13311-022-01288-7_bib30","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1074\/jbc.275.12.8812","article-title":"Membrane association and protein conformation of \u03b1-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations","volume":"275","author":"McLean","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-022-01288-7_bib31","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1006\/jmbi.2001.4538","article-title":"Conformational properties of a-synuclein in its free and lipid-associated states","volume":"307","author":"Eliezer","year":"2001","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-022-01288-7_bib32","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1074\/jbc.273.16.9443","article-title":"Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes","volume":"273","author":"Davidson","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-022-01288-7_bib33","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the a-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1007\/s13311-022-01288-7_bib34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding a-synuclein in Parkinson's disease","volume":"18","author":"Kr\u00fcger","year":"1998","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-022-01288-7_bib35","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41467-018-03111-4","article-title":"C-terminal calcium binding of \u03b1-synuclein modulates synaptic vesicle interaction","volume":"9","author":"Lautenschl\u00e4ger","year":"2018","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-022-01288-7_bib36","doi-asserted-by":"crossref","first-page":"13782","DOI":"10.1021\/bi026284c","article-title":"Structural and functional implications of C-terminal regions of a-synuclein","volume":"41","author":"Kim","year":"2002","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-022-01288-7_bib37","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","article-title":"Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal","volume":"8","author":"Maroteaux","year":"1988","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-022-01288-7_bib38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0896-6273(95)90302-X","article-title":"The precursor protein of non-Ab component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system","volume":"14","author":"Iwai","year":"1995","journal-title":"Neuron"},{"key":"10.1007\/s13311-022-01288-7_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener Dis"},{"key":"10.1007\/s13311-022-01288-7_bib40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","article-title":"Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson's disease","volume":"103","author":"Kim","year":"2019","journal-title":"Neuron"},{"key":"10.1007\/s13311-022-01288-7_bib41","doi-asserted-by":"crossref","first-page":"573696","DOI":"10.3389\/fcell.2020.573696","article-title":"Alpha synuclein connects the gut-brain axis in Parkinson's disease patients - a view on clinical aspects, cellular pathology and analytical methodology","volume":"8","author":"Schaeffer","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1007\/s13311-022-01288-7_bib42","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1126\/science.1195227","article-title":"Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro","volume":"329","author":"Burr\u00e9","year":"2010","journal-title":"Science"},{"key":"10.1007\/s13311-022-01288-7_bib43","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1523\/JNEUROSCI.20-09-03214.2000","article-title":"Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons","volume":"20","author":"Murphy","year":"2000","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-022-01288-7_bib44","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.1523\/JNEUROSCI.22-20-08797.2002","article-title":"Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein","volume":"22","author":"Cabin","year":"2002","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-022-01288-7_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40478-017-0416-x","article-title":"AAV1\/2-induced overexpression of A53T-\u03b1-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease","volume":"5","author":"Ip","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.1007\/s13311-022-01288-7_bib46","doi-asserted-by":"crossref","first-page":"E115","DOI":"10.1038\/35017124","article-title":"Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?","volume":"2","author":"Goldberg","year":"2000","journal-title":"Nat Cell Biol"},{"key":"10.1007\/s13311-022-01288-7_bib47","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1021\/bi030086j","article-title":"Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease","volume":"42","author":"Volles","year":"2003","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-022-01288-7_bib48","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/jnnp.74.7.852","article-title":"Lewy body cortical involvement may not always predict dementia in Parkinson's disease","volume":"74","author":"Colosimo","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01288-7_bib49","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00401-008-0346-6","article-title":"Applicability of current staging\/categorization of alpha-synuclein pathology and their clinical relevance","volume":"115","author":"Parkkinen","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-022-01288-7_bib50","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1440-1789.2005.00644.x","article-title":"Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject","volume":"25","author":"Parkkinen","year":"2005","journal-title":"Neuropathology"},{"key":"10.1007\/s13311-022-01288-7_bib51","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.1021\/bi020139h","article-title":"Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes","volume":"41","author":"Ding","year":"2002","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-022-01288-7_bib52","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0022-2836(02)00735-0","article-title":"Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils","volume":"322","author":"Lashuel","year":"2002","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-022-01288-7_bib53","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1073\/pnas.97.2.571","article-title":"Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy","volume":"97","author":"Conway","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-022-01288-7_bib54","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbapap.2019.03.001","article-title":"\u03b1-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis","volume":"1867","author":"Mehra","year":"2019","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"10.1007\/s13311-022-01288-7_bib55","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.1007\/s13311-022-01288-7_bib56","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(04)17104-3","article-title":"Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease","volume":"364","author":"Ib\u00e1\u00f1ez","year":"2004","journal-title":"Lancet"},{"key":"10.1007\/s13311-022-01288-7_bib57","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0014-5793(98)01146-6","article-title":"Synthetic filaments assembled from C-terminally truncated \u03b1-synuclein","volume":"436","author":"Crowther","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1007\/s13311-022-01288-7_bib58","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-022-01288-7_bib59","doi-asserted-by":"crossref","first-page":"49071","DOI":"10.1074\/jbc.M208046200","article-title":"Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions","volume":"277","author":"Hasegawa","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-022-01288-7_bib60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"alpha-Synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat Cell Biol"},{"key":"10.1007\/s13311-022-01288-7_bib61","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bbrc.2016.09.109","article-title":"Alpha-synuclein activates BV2 microglia dependent on its aggregation state","volume":"479","author":"Hoffmann","year":"2016","journal-title":"Biochem Biophys Res C"},{"key":"10.1007\/s13311-022-01288-7_bib62","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1096\/fj.04-2751com","article-title":"Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease","volume":"19","author":"Zhang","year":"2005","journal-title":"FASEB J"},{"key":"10.1007\/s13311-022-01288-7_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1326-5-42","article-title":"Fc\u03b3 receptors are required for NF-\u03baB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease","volume":"5","author":"Cao","year":"2010","journal-title":"Mol Neurodegener"},{"key":"10.1007\/s13311-022-01288-7_bib64","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/mds.26377","article-title":"Active immunization therapies for Parkinson's disease and multiple system atrophy","volume":"31","author":"Schneeberger","year":"2016","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-022-01288-7_bib65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/mds.26481","article-title":"Development of Passive Immunotherapies for Synucleinopathies","volume":"31","author":"Bergstr\u00f6m","year":"2016","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-022-01288-7_bib66","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti\u2013\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-022-01288-7_bib67","article-title":"Cinpanemab in early Parkinson's disease: phase 2 SPARK study results","author":"Lang","year":"2021","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-022-01288-7_bib68","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of cinpanemab in early Parkinson's disease","volume":"387","author":"Lang","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01288-7_bib69","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01288-7_bib70","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti\u2013\u03b1-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-022-01288-7_bib71","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson's disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01288-7_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","author":"Masliah","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-022-01288-7_bib73","article-title":"Humanized antibodies that recognize alpha-synuclein","author":"Saldanha","year":"2017","journal-title":"US 9556259 B2 (USA)"},{"key":"10.1007\/s13311-022-01288-7_bib74","article-title":"Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with Lewy Bodies and other \u03b1-synucleinopathies","author":"Nordstr\u00f6m","year":"2015","journal-title":"US 8968734 B2 (USA)"},{"key":"10.1007\/s13311-022-01288-7_bib75","article-title":"Antibodies to alpha-synuclein and uses thereof","author":"Perkinton","year":"2017","journal-title":"WO 2017\/207739 A1 (International)"},{"key":"10.1007\/s13311-022-01288-7_bib76","article-title":"Agents, uses and methods for the treatment of synucleinopathy","author":"Kallunki","year":"2018","journal-title":"WO 2018\/091444 A1 (International)"},{"key":"10.1007\/s13311-022-01288-7_bib77","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-022-01288-7_bib78","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nature15368","article-title":"Structure of the toxic core of \u03b1-synuclein from invisible crystals","volume":"525","author":"Rodriguez","year":"2015","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01288-7_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","author":"Schofield","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-022-01288-7_bib80","unstructured":"Lundbeck. Investor & Analyst presentation - February 2018. https:\/\/investor.lundbeck.com\/static-files\/c9221a6f-7d35-45f4-8ffc-29c24f59be2e. Accessed 21 May\u00a02020."},{"key":"10.1007\/s13311-022-01288-7_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/biom12020168","article-title":"Passive immunization in alpha-synuclein preclinical animal models","author":"Folke","year":"2022","journal-title":"Biomolecules"},{"key":"10.1007\/s13311-022-01288-7_bib82","doi-asserted-by":"crossref","first-page":"1994690","DOI":"10.1080\/19420862.2021.1994690","article-title":"Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies","volume":"13","author":"Fjord-Larsen","year":"2021","journal-title":"MAbs"},{"key":"10.1007\/s13311-022-01288-7_bib83","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.4049\/jimmunol.159.7.3372","article-title":"Flexibility of human IgG subclasses","volume":"159","author":"Roux","year":"1997","journal-title":"J Immunol"},{"key":"10.1007\/s13311-022-01288-7_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: From structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-022-01288-7_bib85","unstructured":"AstraZeneca. Delivering the next wave of scientific innovation, 2017-A year in review. 2017."},{"key":"10.1007\/s13311-022-01288-7_bib86","article-title":"Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders","author":"Lannfelt","year":"2018","journal-title":"EP 2282758 B1 (Europe)"},{"key":"10.1007\/s13311-022-01288-7_bib87","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jaut.2018.10.006","article-title":"IgG Fc N-glycosylation: Alterations in neurologic diseases and potential therapeutic target?","volume":"96","author":"Kronimus","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1007\/s13311-022-01288-7_bib88","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody Aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01288-7_bib89","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/jnc.14207","article-title":"Vaccination strategies in tauopathies and synucleinopathies","volume":"143","author":"Braczynski","year":"2017","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-022-01288-7_bib90","unstructured":"Genmab. Lu AF82422. https:\/\/www.genmab.com\/product-pipeline\/products-in-development\/lu-af82422. Accessed 20 May 2020."},{"key":"10.1007\/s13311-022-01288-7_bib91","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","article-title":"The twilight of immunity: emerging concepts in aging of the immune system","volume":"19","author":"Nikolich-\u017dugich","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1007\/s13311-022-01288-7_bib92","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after A 42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01288-7_bib93","doi-asserted-by":"crossref","first-page":"948","DOI":"10.4161\/hv.6.11.13217","article-title":"AFFITOME\u00ae technology in neurodegenerative diseases: The doubling advantage","volume":"6","author":"Schneeberger","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1007\/s13311-022-01288-7_bib94","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1353-8020(11)70006-2","article-title":"Vaccination for Parkinson's disease","volume":"18","author":"Schneeberger","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-022-01288-7_bib95","article-title":"Method for vaccination against a self-antigen in a human patient","author":"Galabova","year":"2017","journal-title":"WO 2017\/076873 A1 (International)"},{"key":"10.1007\/s13311-022-01288-7_bib96","article-title":"Mimotope","author":"Mandler","year":"2009","journal-title":"WO 2009\/103105 A2 (International)"},{"key":"10.1007\/s13311-022-01288-7_bib97","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/mds.28218","article-title":"A phase 1 randomized trial of specific active \u03b1-synuclein immunotherapies PD01A and PD03A in multiple system atrophy","volume":"35","author":"Meissner","year":"2020","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-022-01288-7_bib98","article-title":"Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type","author":"Wang","year":"2014","journal-title":"WO 2014\/143087 A1 (International)"},{"key":"10.1007\/s13311-022-01288-7_bib99","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.vaccine.2005.01.007","article-title":"Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications","volume":"23","author":"Wang","year":"2005","journal-title":"Vaccine"},{"key":"10.1007\/s13311-022-01288-7_bib100","article-title":"Artificial promiscuous T helper cell epitopes that facilitate targeted antibody production with limited T cell inflammatory response","author":"Wang","year":"2019","journal-title":"WO 2019\/213555 A1 (International)"},{"key":"10.1007\/s13311-022-01288-7_bib101","article-title":"Peptide immunogens from the C-terminal end of alpha-synuclein protein and formulations for treatment of synucleinopathies","author":"Wang","year":"2018","journal-title":"WO 2018\/232369 A1 (International)"},{"key":"10.1007\/s13311-022-01288-7_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/mds.29016","article-title":"A Randomized First-in-Human Study With UB-312, a UBITh\u00ae \u03b1-Synuclein Peptide Vaccine","author":"Yu","year":"2022","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-022-01288-7_bib103","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jalz.2013.03.007","article-title":"Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU\/US\/CTAD Task Force","volume":"9","author":"Vellas","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1007\/s13311-022-01288-7_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-018-0245-9","article-title":"Tau oligomers mediate \u03b1-synuclein toxicity and can be targeted by immunotherapy","volume":"13","author":"Gerson","year":"2018","journal-title":"Mol Neurodegener"},{"key":"10.1007\/s13311-022-01288-7_bib105","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.bbapap.2018.10.006","article-title":"Disruptive membrane interactions of alpha-synuclein aggregates","volume":"1867","author":"Iyer","year":"2019","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"10.1007\/s13311-022-01288-7_bib106","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1808-9","article-title":"Regulation of \u03b1-synuclein by chaperones in mammalian cells","volume":"577","author":"Burmann","year":"2020","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01288-7_bib107","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40120-018-0122-z","article-title":"Emerging immunotherapies for Parkinson disease","volume":"8","author":"Zella","year":"2019","journal-title":"Neurol Ther"},{"key":"10.1007\/s13311-022-01288-7_bib108","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3233\/JPD-150630","article-title":"Immunotherapy in Parkinson's disease: Micromanaging alpha-synuclein aggregation","volume":"5","author":"George","year":"2015","journal-title":"J Parkinson's Dis"},{"key":"10.1007\/s13311-022-01288-7_bib109","article-title":"Progress of immunotherapy of anti-\u03b1-synuclein in Parkinson's disease","author":"Wang","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1007\/s13311-022-01288-7_bib110","doi-asserted-by":"crossref","first-page":"105543","DOI":"10.1016\/j.nbd.2021.105543","article-title":"ABBV-0805, a novel antibody selective for soluble aggregated \u03b1-synuclein, prolongs lifespan and prevents buildup of \u03b1-synuclein pathology in mouse models of Parkinson's disease","volume":"161","author":"Nordstr\u00f6m","year":"2021","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-022-01288-7_bib111","article-title":"Compositions and methods for treating synucleinopathies","author":"Penner","year":"2018","journal-title":"WO 2018\/178950 A1 (International)"},{"key":"10.1007\/s13311-022-01288-7_bib112","article-title":"Human anti-alpha-synuclein autoantibodies","author":"Weihofen","year":"2010","journal-title":"WO 2010\/069603 A1 (International)"},{"key":"10.1007\/s13311-022-01288-7_bib113","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3233\/JPD-189004","article-title":"Clinical trial highlights: Targeting alpha-synuclein","volume":"9","author":"McFarthing","year":"2019","journal-title":"J Parkinson's Dis"},{"key":"10.1007\/s13311-022-01288-7_bib114","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/imt-2017-0146","article-title":"Immunologic treatment of Parkinson ' s disease","volume":"10","author":"Jankovic","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1007\/s13311-022-01288-7_bib115","article-title":"Determination of Parkinson's disease","author":"Czech","year":"2020","journal-title":"WO 2020\/033756 A1 (International)"},{"key":"10.1007\/s13311-022-01288-7_bib116","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/imt.13.162","article-title":"Immunotherapy targeting \u03b1-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders","volume":"6","author":"Lindstr\u00f6m","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1007\/s13311-022-01288-7_bib117","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamaneurol.2018.0346","article-title":"Challenges in passive immunization strategies to treat Parkinson disease","volume":"75","author":"Manfredsson","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01288-7_bib118","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies - implications for Parkinson's disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-022-01288-7_bib119","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3233\/JPD-212594","article-title":"Safety and tolerability of active immunotherapy targeting \u03b1-synuclein with PD03A in patients with early Parkinson's disease: a randomized, placebo-controlled, phase 1 study","volume":"11","author":"Poewe","year":"2021","journal-title":"J Parkinson's Dis"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01288-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01288-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01288-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:34:30Z","timestamp":1761806070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923001824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":119,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1878747923001824"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01288-7","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01288-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Author(s). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}